FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083150541> ?p ?o ?g. }

• W2083150541 endingPage "1985" @default.
• W2083150541 startingPage "1977" @default.
• W2083150541 abstract "This randomized phase II study investigated pemetrexed in combination with the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab compared with pemetrexed alone as second-line therapy for patients with advanced non-small cell lung cancer.Patients received pemetrexed 500 mg/m every 3 weeks either alone (n = 50) or in combination with matuzumab at either 800 mg weekly (n = 51) or 1600 mg every 3 weeks (n = 47). The primary end point was objective response, as assessed by an independent review committee.Tumor EGFR expression was detected in 87% of randomized patients. The objective response rate for the pooled matuzumab-treated arms was 11% compared with 5% for pemetrexed alone (p = 0.332). Apart from one patient in the pemetrexed alone group, all responses occurred in patients whose tumors expressed EGFR. The objective response rate for patients receiving weekly matuzumab was 16% compared with 2% for those receiving matuzumab every 3 weeks. There was also a trend for improved overall survival in patients receiving matuzumab weekly versus every 3 weeks (12.4 months versus 5.9 months, respectively, versus 7.9 months for pemetrexed alone). The combination of pemetrexed and matuzumab demonstrated an acceptable safety profile, with the most common grade 3/4 adverse event being neutropenia.Although the analysis on the pooled matuzumab-treated arms did not demonstrate a statistically significant improvement in objective response for the addition of matuzumab to pemetrexed compared with pemetrexed alone, the trends for improvement in objective response and overall survival for pemetrexed plus weekly matuzumab compared with pemetrexed alone warrant confirmation in additional clinical trials." @default.
• W2083150541 created "2016-06-24" @default.
• W2083150541 creator A5002306737 @default.
• W2083150541 creator A5008663847 @default.
• W2083150541 creator A5012074807 @default.
• W2083150541 creator A5013804417 @default.
• W2083150541 creator A5015522691 @default.
• W2083150541 creator A5020824873 @default.
• W2083150541 creator A5025701159 @default.
• W2083150541 creator A5026119562 @default.
• W2083150541 creator A5032869739 @default.
• W2083150541 creator A5033290912 @default.
• W2083150541 creator A5050185260 @default.
• W2083150541 creator A5063926074 @default.
• W2083150541 creator A5068652420 @default.
• W2083150541 creator A5078629724 @default.
• W2083150541 creator A5087541775 @default.
• W2083150541 date "2010-12-01" @default.
• W2083150541 modified "2023-09-27" @default.
• W2083150541 title "Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer" @default.
• W2083150541 cites W1839238860 @default.
• W2083150541 cites W1969503710 @default.
• W2083150541 cites W1983523103 @default.
• W2083150541 cites W1992183189 @default.
• W2083150541 cites W1998085563 @default.
• W2083150541 cites W2039964383 @default.
• W2083150541 cites W2040581402 @default.
• W2083150541 cites W2040662520 @default.
• W2083150541 cites W2067597961 @default.
• W2083150541 cites W2072734055 @default.
• W2083150541 cites W2099725888 @default.
• W2083150541 cites W2103384680 @default.
• W2083150541 cites W2104748005 @default.
• W2083150541 cites W2105026490 @default.
• W2083150541 cites W2122343496 @default.
• W2083150541 cites W2122553809 @default.
• W2083150541 cites W2125558775 @default.
• W2083150541 cites W2126427337 @default.
• W2083150541 cites W2130626169 @default.
• W2083150541 cites W2130652363 @default.
• W2083150541 cites W2134667653 @default.
• W2083150541 cites W2138297714 @default.
• W2083150541 cites W2139939379 @default.
• W2083150541 cites W2142850084 @default.
• W2083150541 cites W2145835533 @default.
• W2083150541 cites W2150923784 @default.
• W2083150541 cites W2153942353 @default.
• W2083150541 cites W2166084034 @default.
• W2083150541 cites W2168340462 @default.
• W2083150541 cites W4293241248 @default.
• W2083150541 doi "https://doi.org/10.1097/jto.0b013e3181f4a5c9" @default.
• W2083150541 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20978446" @default.
• W2083150541 hasPublicationYear "2010" @default.
• W2083150541 type Work @default.
• W2083150541 sameAs 2083150541 @default.
• W2083150541 citedByCount "50" @default.
• W2083150541 countsByYear W20831505412012 @default.
• W2083150541 countsByYear W20831505412013 @default.
• W2083150541 countsByYear W20831505412014 @default.
• W2083150541 countsByYear W20831505412015 @default.
• W2083150541 countsByYear W20831505412016 @default.
• W2083150541 countsByYear W20831505412017 @default.
• W2083150541 countsByYear W20831505412018 @default.
• W2083150541 countsByYear W20831505412019 @default.
• W2083150541 countsByYear W20831505412020 @default.
• W2083150541 countsByYear W20831505412021 @default.
• W2083150541 crossrefType "journal-article" @default.
• W2083150541 hasAuthorship W2083150541A5002306737 @default.
• W2083150541 hasAuthorship W2083150541A5008663847 @default.
• W2083150541 hasAuthorship W2083150541A5012074807 @default.
• W2083150541 hasAuthorship W2083150541A5013804417 @default.
• W2083150541 hasAuthorship W2083150541A5015522691 @default.
• W2083150541 hasAuthorship W2083150541A5020824873 @default.
• W2083150541 hasAuthorship W2083150541A5025701159 @default.
• W2083150541 hasAuthorship W2083150541A5026119562 @default.
• W2083150541 hasAuthorship W2083150541A5032869739 @default.
• W2083150541 hasAuthorship W2083150541A5033290912 @default.
• W2083150541 hasAuthorship W2083150541A5050185260 @default.
• W2083150541 hasAuthorship W2083150541A5063926074 @default.
• W2083150541 hasAuthorship W2083150541A5068652420 @default.
• W2083150541 hasAuthorship W2083150541A5078629724 @default.
• W2083150541 hasAuthorship W2083150541A5087541775 @default.
• W2083150541 hasBestOaLocation W20831505411 @default.
• W2083150541 hasConcept C126322002 @default.
• W2083150541 hasConcept C141071460 @default.
• W2083150541 hasConcept C143998085 @default.
• W2083150541 hasConcept C168563851 @default.
• W2083150541 hasConcept C197934379 @default.
• W2083150541 hasConcept C203092338 @default.
• W2083150541 hasConcept C2776256026 @default.
• W2083150541 hasConcept C2776694085 @default.
• W2083150541 hasConcept C2777063308 @default.
• W2083150541 hasConcept C2777240266 @default.
• W2083150541 hasConcept C2778239845 @default.
• W2083150541 hasConcept C31760486 @default.
• W2083150541 hasConcept C71924100 @default.
• W2083150541 hasConceptScore W2083150541C126322002 @default.
• W2083150541 hasConceptScore W2083150541C141071460 @default.

• next